A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO® (imetelstat), harnesses Nobel Prize winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the disease of these hematologic malignancies. We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 223M | 223M | 89M | - | - | - |
| Net Income | -84M | -84M | -175M | -184M | -142M | -116M |
| EPS | $-0.13 | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
| Free Cash Flow | -111M | -111M | -219M | -169M | -128M | -96M |
| ROIC | -20.0% | -22.4% | -43.8% | -65.1% | -128.8% | -65.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.54 | 0.54 | 0.60 | 0.54 | 0.96 | 0.44 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -69M | -69M | -174M | -194M | -139M | -114M |
| Operating Margin | -30.7% | -30.7% | -194.3% | - | - | - |
| ROE | -37.0% | -33.0% | -62.3% | -74.3% | -177.4% | -91.8% |
| Shares Outstanding | 642M | 642M | 647M | 575M | 384M | 332M |
GERON CORP passes 0 of 9 quality checks, indicating weak fundamentals.
GERON CORP (GERN) has a 5-year average return on invested capital (ROIC) of -65.2%. This is below average and may indicate limited pricing power.
GERON CORP (GERN) has a market capitalization of $1.1B. It is classified as a small-cap stock.
GERON CORP (GERN) does not currently pay a regular dividend.
GERON CORP (GERN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
GERON CORP (GERN) reported annual revenue of $223 million in its most recent fiscal year, based on SEC EDGAR filings.
GERON CORP (GERN) has a net profit margin of -37.4%. The company is currently unprofitable.
GERON CORP (GERN) generated $-111 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
GERON CORP (GERN) has a debt-to-equity ratio of 0.54. This indicates moderate leverage.
GERON CORP (GERN) reported earnings per share (EPS) of $-0.13 in its most recent fiscal year.
GERON CORP (GERN) has a return on equity (ROE) of -33.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for GERON CORP (GERN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GERON CORP (GERN) has a book value per share of $0.35, based on its most recent annual SEC filing.
No recent press releases.